Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the GI tract. Over 80% of GISTs harbor activating mutations in c-Kit and approximately 5-7% in PDGFRA. Although these mutations are oncogenic, they also predict response to targeted therapy (imatinib) and provide prognostic information. Exon 11 mutations in c-Kit predict more favorable prognosis and response to imatinib, while mutations in exon 9 predict poor prognosis and require a higher dose of therapy. PDGFRA D842V mutation also causes resistance to imatinib. Mutations in c-Kit and PDGFRA are mutually exclusive. Available Kits for GIST : S.No. Product Name Catalog Number Platform 1 GIST Mutation Detection Kit GIST-RT44 For Real-Time PCR.
Available kits for GIST :
|S.No.||Product Name||Catalog Number||Platform|
|1||GIST Mutation Detection Kit||GIST-RT44||For Real-Time PCR|
EntroGen’s GIST mutation screening panel is a real-time polymerase chain reaction (PCR)-based assay that uses allele-specific primers to identify the presence of somatic mutations in c-KIT and PDGFRA genes.
The assessment procedure involves three simple steps:
1) Isolation of DNA from tumor biopsies, paraffin-embedded sections (FFPE), or fresh frozen tumors.
2) Amplification using the provided reagents.
3) Data analysis and interpretation using the real-time PCR software or provided analysis worksheet
EntroGen’s GIST mutation screening panel requires a real-time PCR instrument capable of detection FAM, VIC, ROX, and CY5 fluorescent probes.
This test includes reagents required for the PCR amplification/detection, as well as validated reaction controls. Columns and reagents for DNA isolation are not included.